series-a
Stage
2020
Founded
2
Investors
About
AnaCardio is a clinical-stage biopharmaceutical company developing novel drugs to treat heart failure, focusing on improving cardiac contractility through a unique mechanism based on the ghrelin signaling pathway.
Explore AnaCardio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.